Search

Your search keyword '"OVERALL survival"' showing total 8 results
8 results on '"OVERALL survival"'

2. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.

Author

CLARKE, HANNAH and HOLLASCH, MEGAN

Subjects
*THERAPEUTIC use of monoclonal antibodies, *RISK assessment, *PLACEBOS, *DEATH, *CANCER relapse, *DRUG side effects, *PATIENT safety, *CLINICAL trials, *TERMINATION of treatment, *NEPHRECTOMY, *RENAL cell carcinoma, *DISEASE relapse, *PROGRESSION-free survival, *TUMOR classification, *OVERALL survival, *PATIENT aftercare, *EVALUATION, *DISEASE risk factors
Abstract

The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.

Published
2024

3. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.

Author

Joszt, Laura

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *DISEASE progression, *EVALUATION of human services programs, *COMBINATION drug therapy, *EPIDERMAL growth factor receptors, *LUNG tumors, *CHEMORADIOTHERAPY, *MEDICAL care research, *TUMOR classification, *TREATMENT effectiveness, *CANCER patients, *ANAPLASTIC lymphoma kinase, *SURVIVAL analysis (Biometry), *QUALITY of life, *PROGRESSION-free survival, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival, *CHEMICAL inhibitors
Abstract

The article reports on the results of the 3 EMPOWER-Lung 3 study that were presented at the 2023 European Society for Medical Oncology Congress, showing that cemiplimab plus chemotherapy showed better favorable survival benefits and patient-reported outcomes (PRO) in patients with advanced non-small cell lung cancer (NSCLC). Also cited are the median overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) study results.

Published
2023

4. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.

Author

Ryan, Chris

Subjects
*THERAPEUTIC use of antineoplastic agents, *DISEASE progression, *CARBOPLATIN, *CHEMORADIOTHERAPY, *PROGRESSION-free survival, *PACLITAXEL, *INDUCTION chemotherapy, *OVERALL survival, CERVIX uteri tumors
Abstract

The article reports on the results of the phase 3 INTERLACE trial showing that induction chemotherapy followed by chemoradiation lowered by 35% the risk of disease progression or death as compared to chemoradiation alone in patients with locally advanced cervical cancer. According to lead study author Mary McCormack, induction chemotherapy with paclitaxel and carboplatin should be considered as a standard treatment.

Published
2023

5. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.

Author

CLARKE, HANNAH

Subjects
*PREVENTION of drug side effects, *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *PATIENT safety, *INVESTIGATIONAL drugs, *TERMINATION of treatment, *CLINICAL trials, *CANCER chemotherapy, *METASTASIS, *DRUG approval, *ENDOMETRIAL tumors, *COMBINED modality therapy, *DRUG efficacy, *PROGRESSION-free survival, *LUNG cancer, *OVERALL survival, *DISEASE progression, *HEPATOCELLULAR carcinoma, TUMOR surgery, BLADDER tumors, BILE duct tumors
Abstract

The article focuses on a news release from AstraZeneca on the results of the phase three NIAGARA trial, which shows the effectiveness of the combination of durvalumab and chemotherapy in improving event-free survival and overall survival in patients with muscle-invasive bladder cancer. Topics discussed include the safety of durvalumab in the trial, and the selection of the participants.

Published
2024

6. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.

Author

CLARKE, HANNAH

Subjects
*NON-muscle invasive bladder cancer, *CYSTOSCOPY, *EARLY detection of cancer, *DISEASE relapse, *PROGRESSION-free survival, *DISEASE progression, *OVERALL survival
Abstract

The article discusses 2024 data which showed that blue light cystoscopy (BLC) is linked to improved outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) compared to white light cystoscopy (WLC). Topics covered include the comparatively lower recurrence risk and progression risk for patients following BLC, and the latter's improved overall survival. Also noted is improved tumor visualization's help in determining intravesical therapy use, such as Bacillus Calmette-Guerin (BCG).

Published
2024

7. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG efficacy, *PATIENT aftercare, *COMBINATION drug therapy, *COLLEGE teacher attitudes, *TREATMENT effectiveness, *BENZAMIDE, *PROGRESSION-free survival, *OVERALL survival, *THERAPEUTICS
Abstract

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.

Published
2023

8. Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.

Author

McNulty, Rose

Subjects
*MULTIPLE myeloma treatment, *DISEASE progression, *BONE marrow transplantation, *TREATMENT effectiveness, *PROGRESSION-free survival, *OVERALL survival
Abstract

The article discusses research that shows allogeneic stem cell transplant (allo-SCT) may not significantly benefit most patients with multiple myeloma. It considers the overall survival and progression-free survival after allo-SCT. The feasibility of alternatives such as CAR T-cell or bispecific T-cell engager therapies is suggested. The findings were presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results